Applications, hearings, determinations, etc.: Knoll Pharmaceutical Co.,

[Federal Register: July 23, 2001 (Volume 66, Number 141)]

[Notices]

[Page 38323]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr23jy01-112]

[[Page 38323]]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on March 7, 2001, Abbott Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson Road, Whippany, New Jersey 07981, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug

Schedule

Dihydromorphine (9145)..................... I Hydromorphone (9150)....................... II

The firm plans to produce bulk product and finished dosage units for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comment or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filedno later than September 21, 2001.

Dated: July 13, 2001. Laura M. Nagel, Deputy Assitant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 01-18214Filed7-20-01; 8:45 am]

BILLING CODE 4410-09-M